Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug
Velasco, Roser (Universitat Autònoma de Barcelona. Institut de Neurociències)
Marco, Carla (Hospital Universitari de Bellvitge)
Domingo-Domenech, Eva (Institut d'Investigació Biomèdica de Bellvitge)
Stradella, Agostina (Institut d'Investigació Biomèdica de Bellvitge)
Santos Vivas, Cristina (Institut d'Investigació Biomèdica de Bellvitge)
Laquente, Berta (Institut d'Investigació Biomèdica de Bellvitge)
Ferrer, German (Hospital Universitari de Bellvitge)
Argyriou, Andreas A. (Agios Andreas General Hospital of Patras)
Bruna, Jordi (Universitat Autònoma de Barcelona. Institut de Neurociències)

Data:	2024
Resum:	A real-time biomarker in chemotherapy-induced peripheral neurotoxicity (CIPN) would be useful for clinical decision-making during treatment. Neurofilament light chain (NfL) can be detected in blood in the case of neuroaxonal damage. The aim of the study was to compare the levels of plasma NfL (pNfL) according to the type of chemotherapeutic agent and the severity of CIPN. This single-center prospective observational longitudinal study included patients treated with paclitaxel (TX; n = 34), brentuximab vedotin (BV; n = 29), or oxaliplatin (PT; n = 19). All patients were assessed using the Total Neuropathy Score-clinical version and Common Terminology Criteria for Adverse Events before, during, and up to 6-12 months after the end of treatment. Nerve conduction studies (NCS) were performed before and after chemotherapy discontinuation. Consecutive plasma samples were analyzed for NfL levels using a Simoa ® analyzer. Changes in pNfL were compared between groups and were eventually correlated with clinical and NCS data. Clinically relevant (CR) CIPN was considered to be grade ≥ 2. Eighty-two patients, mostly women (59. 8%), were included. One third of the patients who received TX (29. 4%), BV (31%), or PT (36. 8%) developed CR-CIPN, respectively, without differences among them (p = 0. 854). Although pNfL significantly increased during treatment and decreased throughout the recovery period in all three groups, patients receiving TX showed significantly greater and earlier changes in pNfL levels compared to the other agents (p < 0. 001). A variable change in pNfL is observed depending on the type of agent and mechanism of neurotoxicity with comparable CIPN severity, strongly implying the need to identify different cutoff values for each agent.
Ajuts:	Instituto de Salud Carlos III PI20/00283 Instituto de Salud Carlos III PI21/00181
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biomarkers ; Brentuximab vedotin ; Chemotherapy-induced peripheral neurotoxicity ; Neurofilament light chain ; Oxaliplatin ; Paclitaxel
Publicat a:	European Journal of Neurology, Vol. 31 (july 2024) , ISSN 1468-1331

DOI: 10.1111/ene.16369
PMID: 38952074

9 p, 2.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Neurociències (INc)
Articles > Articles de recerca
Articles > Articles publicats